In the abdomen, the thigh or the upper arm, and the choice does not change how much drug reaches the blood. The Ozempic label names those three areas and states that similar exposure is achieved at each [1]. A model built on 1,612 people with type 2 diabetes in five trials found no clinically relevant effect of injection site on exposure [2]. Body weight was the only factor that mattered.
The pen itself sets the timing, not the site. How the first doses are stepped up is covered in the semaglutide starting dose. The tablet form skips injection entirely, and how oral semaglutide is taken explains its own rules.
What the Ozempic label says about injection sites
The dosing section is short. Ozempic goes under the skin of the abdomen, thigh or upper arm [1]. When the same body region is used each week, a different spot within it is used each time. The pharmacology section adds the key sentence: similar exposure is achieved in all three areas.
The Medication Guide and instructions for use add three practical limits [1]:
- In the abdomen, stay at least 2 inches from the belly button.
- Inject under the skin, never into a muscle or a vein.
- Insulin may go in the same body area, but not right next to the Ozempic injection, and never mixed in one syringe.
The Wegovy label, for the 2.4 mg dose of the same drug, says the site and the time of day can change without any change in dose [3]. It also names the same three areas.
Does the injection site change how well Ozempic works?
Not in the blood levels that were measured. The population model pooled 1,612 people from five phase 3 trials that ran 30 to 104 weeks [2]. Each person gave up to seven blood samples. Sex, age, race, kidney function and injection site had no clinically relevant effect on exposure. Only body weight did.
A second model used denser sampling from nine clinical pharmacology trials: 353 people and 10,573 concentration values [4]. It found minor differences between injection sites in bioavailability. The authors still describe semaglutide’s behavior as predictable across populations and routes. Minor and not clinically relevant are the two findings side by side.
What neither model measured is weight loss or blood sugar by site. No trial randomized people to the arm or the abdomen and compared outcomes. The exposure result is the closest evidence, and it is a blood-level result.
Zepbound and Mounjaro: where to inject tirzepatide
The tirzepatide labels list the same three areas with one condition. You or another person can inject the abdomen or thigh, and the back of the upper arm is for another person to inject [5] [7]. The Zepbound label also states that similar exposure was achieved in the abdomen, thigh or upper arm. Mean absolute bioavailability after an injection under the skin is 80 percent. How long the drug then lingers is set out in how long Zepbound stays in your system.
Skin reactions at the site are counted separately from exposure. Injection site reactions affected 0.2 percent of people on Ozempic in placebo-controlled trials [1]. On Zepbound they reached 6 to 8 percent against 2 percent on placebo [5]. They were more frequent in people who developed antibodies to tirzepatide, at 11.3 percent against 1 percent.
Why rotate injection sites
Every label asks for a new spot with each dose [1] [3] [5]. None of the sources here reports a trial that tested rotation against repeated use of one spot. The instruction is a labeling rule, and its benefit has not been measured for these drugs.
One published case shows a site-specific problem. A 44-year-old man developed focal, nerve-type abdominal pain that began with his tirzepatide injections [6]. Examination found anterior cutaneous nerve entrapment, a trapped nerve in the abdominal wall. The pain improved after injections moved away from the abdomen and medication was started. It is one case, and no rate can be drawn from it.